The Role of Peroxisome Proliferator-Activated Receptors in Polycystic Ovary Syndrome.
Iason PsilopatisKleio VrettouEleni NousiopoulouKostantinos PalamarisStamatios TheocharisPublished in: Journal of clinical medicine (2023)
Polycystic ovary syndrome (PCOS) constitutes the most common endocrine disorder in women of reproductive age. Patients usually suffer from severe menstrual irregularities, skin conditions, and insulin resistance-associated health conditions. Peroxisome proliferator-activated receptors (PPARs) are nuclear receptor proteins that regulate gene expression. In order to investigate the role of PPARs in the pathophysiology of PCOS, we conducted a literature review using the MEDLINE and LIVIVO databases and were able to identify 74 relevant studies published between 2003 and 2023. Different study groups reached contradictory conclusions in terms of PPAR expression in PCOS. Interestingly, numerous natural agents were found to represent a novel, potent anti-PCOS treatment alternatives. In conclusion, PPARs seem to play a significant role in PCOS.
Keyphrases
- polycystic ovary syndrome
- insulin resistance
- gene expression
- adipose tissue
- high fat diet
- skeletal muscle
- metabolic syndrome
- end stage renal disease
- ejection fraction
- type diabetes
- newly diagnosed
- high fat diet induced
- healthcare
- poor prognosis
- dna methylation
- public health
- risk assessment
- binding protein
- health information
- chronic kidney disease
- deep learning
- prognostic factors
- machine learning
- artificial intelligence
- peritoneal dialysis
- weight loss
- climate change
- soft tissue
- health promotion
- fatty acid